Research Article

Resveratrol affects ccRCC cell senescence and macrophage polarization by regulating the stability of CCNB1 by RBM15

*Author for correspondence: Tel.: +86 027 8366 5014;

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430030, Hubei, China

Search for more papers by this author

Chang Liu

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430030, Hubei, China

Search for more papers by this author

Tao Ye

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430030, Hubei, China

Search for more papers by this author

Yucong Zhang

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430030, Hubei, China

Search for more papers by this author

Yuan Chen

Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430030, Hubei, China

Search for more papers by this author

Published Online:1 Nov 2023https://doi.org/10.2217/epi-2023-0150

View article

Abstract

Aim: The present study sought to investigate the therapeutic effect of resveratrol on clear cell renal cell carcinoma. Materials & methods: Cell Counting Kit-8 and 5-ethynyl-2′-deoxyuridine assays were used to verify the cell proliferation. Transwell, real-time quantitative transcription PCR, western blot and β-galactosidase staining were used to verify the migration, macrophage polarization and senescence. The tumor inhibitory effect of resveratrol on clear cell renal cell carcinoma was verified in vivo. Results: This study confirmed that resveratrol could affect the stability of CCNB1 mRNA mediated by RBM15 and inhibit the cancer process by inhibiting the expression of EP300/CBP from the perspective of cell senescence. Conclusion: Resveratrol is able to treat clear cell renal cell carcinoma through RBM15-induced cell senescence.

Tweetable abstract

A recent study has shown that resveratrol RBM15 mRNA stability and suppressing cancer cell proliferation, offering a promising therapeutic approach for kidney cancer. #Resveratrol #Kidney Cancer

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Xi W, Chen X, Sun J et al. Combined treatment with valproic acid and 5-Aza-2′-deoxycytidine synergistically inhibits human clear cell renal cell carcinoma growth and migration. Med. Sci. Monit. 24, 1034–1043 (2018).
Medline CASGoogle Scholar
2. Rausch M, Weiss A, Zoetemelk M et al. Optimized combination of HDACI and TKI efficiently inhibits metabolic activity in renal cell carcinoma and overcomes sunitinib resistance. Cancers (Basel). 12(11), (2020).
MedlineGoogle Scholar
3. Jiang N, Niu G, Pan YH et al. CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma. EBioMedicine. 53, 102692 (2020).
MedlineGoogle Scholar
4. Chen J, Ren JJ, Cai J, Wang X. Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: a systematic review and meta-analysis. Medicine (Baltimore). 100(31), e26788 (2021).
Medline CASGoogle Scholar
5. He L, Li H, Wu A et al. Functions of N6-methyladenosine and its role in cancer. Mol. Cancer 18(1), 176 (2019).
MedlineGoogle Scholar
6. Liu L, Li H, Hu D et al. Insights into N6-methyladenosine and programmed cell death in cancer. Mol. Cancer 21(1), 32 (2022).
Medline CASGoogle Scholar
7. Wang S, Gao S, Zeng Y et al. N6-methyladenosine reader YTHDF1 promotes ARHGEF2 translation and RhoA signaling in colorectal cancer. Gastroenterology 162(4), 1183–1196 (2022).
Medline CASGoogle Scholar
8. Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in cancer progression. Mol. Cancer. 19(1), 88 (2020). • This research idea provides the basis.
Medline CASGoogle Scholar
9. Ren B, Kwah MX, Liu C et al. Resveratrol for cancer therapy: challenges and future perspectives. Cancer Lett. 515, 63–72 (2021). •• This report provided significant guidance for drug selection in this study.
Medline CASGoogle Scholar
10. Carter LG, D'orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer. 21(3), R209–225 (2014).
Medline CASGoogle Scholar
11. Zaffaroni N, Beretta GL. Resveratrol and Prostate Cancer: The Power of Phytochemicals. Curr Med Chem. 28(24), 4845–4862 (2021).
Medline CASGoogle Scholar
12. Gu YR, Kim J, Na JC, Han WK. Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma. PLOS ONE 17(6), e0269432 (2022).
Medline CASGoogle Scholar
13. Galiniak S, Aebisher D, Bartusik-Aebisher D. Health benefits of resveratrol administration. Acta Biochim. Pol. 66(1), 13–21 (2019).
Medline CASGoogle Scholar
14. Rauf A, Imran M, Butt MS et al. Resveratrol as an anti-cancer agent: a review. Crit. Rev. Food Sci. Nutr. 58(9), 1428–1447 (2018).
MedlineGoogle Scholar
15. Yue B, Song C, Yang L et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol. Cancer. 18(1), 142 (2019).
MedlineGoogle Scholar
16. Zeng X, Chen K, Li L et al. Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11. Free Radic. Biol. Med. 184, 135–147 (2022). • This research idea provides the basis for this work.
Medline CASGoogle Scholar
17. Bian Y, Wang X, Zheng Z et al. Resveratrol drives cancer cell senescence via enhancing p38MAPK and DLC1 expressions. Food Funct. 13(6), 3283–3293 (2022).
Medline CASGoogle Scholar
18. Ma F, Ma Y, Liu K et al. Resveratrol induces DNA damage-mediated cancer cell senescence through the DLC1-DYRK1A-EGFR axis. Food Funct. 14(3), 1484–1497 (2023).
Medline CASGoogle Scholar
19. Zhang H, Zhang X, Li X et al. Effect of CCNB1 silencing on cell cycle, senescence, and apoptosis through the p53 signaling pathway in pancreatic cancer. J. Cell Physiol. 234(1), 619–631 (2018).
MedlineGoogle Scholar
20. Yang D, Guo Q, Liang Y et al. Wogonin induces cellular senescence in breast cancer via suppressing TXNRD2 expression. Arch Toxicol. 94(10), 3433–3447 (2020).
Medline CASGoogle Scholar
21. Vicente R, Mausset-Bonnefont AL, Jorgensen C et al. Cellular senescence impact on immune cell fate and function. Aging Cell. 15(3), 400–406 (2016). • This study referred to the role of SASP in cell senescence and tumor progression.
Medline CASGoogle Scholar
22. Lu L, Li Y, Wen H, Feng C. Overexpression of miR-15b promotes resistance to sunitinib in renal cell carcinoma. J. Cancer. 10(15), 3389–3396 (2019).
Medline CASGoogle Scholar
23. Ansari MSZ, Stagni V, Iuzzolino A et al. Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells. Cancer Gene Ther. doi: 10.1038/s41417-022-00524-8 (2022).
MedlineGoogle Scholar
24. Feng Y, Wang X, Xu L et al. The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence. Febs J. 276(15), 4197–4206 (2009).
Medline CASGoogle Scholar
25. Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 34(23–24), 1565–1576 (2020).
Medline CASGoogle Scholar
26. Cuollo L, Antonangeli F, Santoni A, Soriani A. The senescence-associated secretory phenotype (SASP) in the challenging future of cancer therapy and age-related diseases. Biology (Basel). 9(12), (2020).
MedlineGoogle Scholar
27. He S, Sharpless NE. Senescence in health and disease. Cell 169(6), 1000–1011 (2017).
Medline CASGoogle Scholar
28. Liu Y, Yang S, Wang K et al. Cellular senescence and cancer: Focusing on traditional Chinese medicine and natural products. Cell Prolif. 53(10), e12894 (2020).
MedlineGoogle Scholar
29. Mabrouk N, Ghione S, Laurens V et al. Senescence and Cancer: Role of Nitric Oxide (NO) in SASP. Cancers (Basel). 12(5), (2020).
MedlineGoogle Scholar
30. Takasugi M, Yoshida Y, Ohtani N. Cellular senescence and the tumour microenvironment. Mol. Oncol. 16(18), 3333–3351 (2022).
Medline CASGoogle Scholar
31. Wang B, Kohli J, Demaria M. Senescent cells in cancer therapy: friends or foes? Trends Cancer 6(10), 838–857 (2020).
Medline CASGoogle Scholar
32. Sun H, Wang H, Wang X et al. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Theranostics 10(15), 6928–6945 (2020).
Medline CASGoogle Scholar
33. Wang Y, Chen Y, Guan L et al. Carnitine palmitoyltransferase 1C regulates cancer cell senescence through mitochondria-associated metabolic reprograming. Cell Death Differ. 25(4), 735–748 (2018).
Medline CASGoogle Scholar
34. Chen KY, Chen CC, Chang YC, Chang MC. Resveratrol induced premature senescence and inhibited epithelial-mesenchymal transition of cancer cells via induction of tumor suppressor Rad9. PLOS ONE 14(7), e0219317 (2019).
Medline CASGoogle Scholar
35. Farhadnejad H, Emamat H, Zand H. The effect of resveratrol on cellular senescence in normal and cancer cells: focusing on cancer and age-related diseases. Nutr Cancer 71(7), 1175–1180 (2019).
Medline CASGoogle Scholar
36. Li YR, Li S, Lin CC. Effect of resveratrol and pterostilbene on aging and longevity. Biofactors. 44(1), 69–82 (2018).
MedlineGoogle Scholar
37. Pyo IS, Yun S, Yoon YE et al. Mechanisms of aging and the preventive effects of resveratrol on age-related diseases. Molecules 25(20), (2020).
MedlineGoogle Scholar
38. Chen EB, Qin X, Peng K et al. HnRNPR-CCNB1/CENPF axis contributes to gastric cancer proliferation and metastasis. Aging (Albany NY). 11(18), 7473–7491 (2019).
Medline CASGoogle Scholar
39. Xia P, Zhang H, Xu K et al. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis. 12(7), 691 (2021).
Medline CASGoogle Scholar
40. Zou Y, Ruan S, Jin L et al. CDK1, CCNB1, and CCNB2 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Med. Sci. Monit. 26, e925289 (2020).
Medline CASGoogle Scholar
41. Shen L, Kang L, Wang D et al. Legumain-deficient macrophages promote senescence of tumor cells by sustaining JAK1/STAT1 activation. Cancer Lett. 472, 40–49 (2020).
Medline CASGoogle Scholar

Vol. 15, No. 18

Supplemental Materials

Metrics

Downloaded 71 times

History

Received 25 April 2023

Accepted 11 October 2023

Published online 1 November 2023

Published in print September 2023

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/epi-2023-0150

Author contributions

Z Chen and C Liu mad substantial contributions to the concept and the design of the manuscript. Z Chen, T Ye and YC to acquisition, analysis and interpretation of the data. All authors have participated to drafting the manuscript, Z Chen and Y Chen revised it critically. All authors read and approved the final version of the manuscript.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the article. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was approved and supervised by the Ethics Committee of the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. The specimens were obtained with the consent of the hospital ethics committee and the informed consent of the patient. In addition, the animal experiment of this study was approved by the ethics committee of our hospital, and the 3R principle was adhered to and supervised by the ethics committee throughout the study design. The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download